Close Menu

More articles about Business, Policy & Funding

The Japanese Ministry of Health, Labor, and Welfare approved the molecularly defined indications based on data from the PAOLA-1, PROfound, and POLO trials.

The company closed a $110 million private investment in public equity financing and announced a new financing for $15 million.

Researchers aim to evaluate the safety and tolerability of the CD19-specific T cells manufactured using Ziopharm's Rapid Personalized Manufacturing process.

Bayer will offer Veracyte's Afirma Xpression Atlas to identify underlying drivers in tumors of late-stage or metastatic thyroid cancer patients resistant to radioactive iodine therapy.

Earlier this year, Novigenix and collaborators were awarded up to €1 million to develop a blood-based multi-omics colorectal cancer assay.

The submission follows recently presented study data showing that the vast majority of patients on ciltacabtagene autoleucel responded to the therapy.

A range of drugs from Agios' cancer pipeline will be transferred to Servier, including two commercial drugs Tibsovo and Idhifa.

Servier will have an exclusive option to research, develop, and commercialize products for up to three of the targets identified by Celsius.

The agency made its decision based on data showing adjuvant Tagrisso decreased the risk of cancer recurrence or death by 80 percent compared to placebo. 

The autologous treatment received conditional approval for relapsed or refractory mantle cell lymphoma patients based on results of the ZUMA-2 trial.

The agency approved the drug based on data from the SOPHIA trial, which showed Margenza improved progression-free survival over Herceptin.

Oncocyte will receive upfront cash payments after transferring and installing DetermaRx, in addition to certain tests after it achieves inclusion in the US Comprehensive Cancer Network.

The PCR-based test detects mutations in the PIK3CA gene that can cause cells to grow uncontrollably, possibly leading to cancer.

The Roche subsidiary will take over development of RLY-1971 and study it in combination with other drugs, such as its KRAS G12C inhibitor GDC-6036.

The decision is based on data from the Phase II HER2CLIMB trial, which evaluated Tukysa in combination with Herceptin and capecitabine.

CHMP issued a positive recommendation for Daiichi Sankyo/AstraZeneca's antibody-drug conjugate following positive results from the DESTINY-Breast01 trial.

The European Commission will review CHMP's opinion based on the Keynote-177 data and is expected to issue a final decision in the first quarter of 2021.

The partners are starting by testing patients with colorectal and thyroid cancers using the 648-gene Tempus xT assay, but could expand to other areas in the future.

The group aims to determine the feasibility of TROLL-2 and TROLL-3 as diagnostic biomarkers for the prediction of treatment efficacy and prognosis in breast cancer.

The agency recommended the drug based on the results from the Phase III ALTA-1L trial, and after Takeda agreed to offer the drug to NHS England at a discount.